Genetic variation determines VEGF-A plasma levels in cancer patients
Federico Innocenti(AbbVie (United States)), Kouros Owzar(Duke University), Ivo Shterev(Statistical and Applied Mathematical Sciences Institute), Yoichi Furukawa(The University of Tokyo), Alexander B. Sibley(Duke University), Alan P. Venook(University of California, San Francisco), Andrew B. Nixon(Duke University), Herbert I. Hurwitz(Duke Medical Center), Jiaxing Lin(Duke University), J. Todd Auman(The University of Texas MD Anderson Cancer Center), Chen Jiang(Auburn University), Mark J. Ratain(University of Chicago), Michiaki Kubo(RIKEN Center for Integrative Medical Sciences), Donna Niedzwiecki(Duke University), Raluca Gordân(Duke University), Ace J. Hatch(Duke Medical Center), Hedy L. Kindler(University of Chicago), Howard L. McLeod(Unknown), Stefanie Denning(University of North Carolina at Chapel Hill), Amy S. Etheridge(University of North Carolina at Chapel Hill)
Cited by 17
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
|Cell|2016|2.4k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k